Publications by authors named "H Sasagawa"
Background: Nivolumab plus ipilimumab (NIVO + IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). While approximately 40% of patients treated with NIVO + IPI achieve a durable response, 20% develop primary resistance with severe consequences. Therefore, there is a clinical need for criteria to select patients suitable for NIVO + IPI therapy to optimize its therapeutic efficacy.
View Article and Find Full Text PDFA young patient diagnosed with advanced colon cancer and liver metastasis was found to have familial adenomatous polyposis (FAP) through comprehensive genomic analysis. Whole-genome array comparative genomic hybridization (aCGH) revealed germline deletions at chromosome 5q22.1-22.
View Article and Find Full Text PDFA recent approach to radiotherapy for prostate cancer is the administration of high doses of radiation to the prostate while minimizing the risk of side effects. Thus, image-guided radiotherapy utilizes advanced imaging techniques and is a feasible strategy for increasing the radiation dose. New radioactive particles are another approach to achieving high doses and safe procedures.
View Article and Find Full Text PDFArticle Synopsis
- A 75-year-old man with prostate cancer and a history of IgG4-related disease rapidly progressed to diffuse large B-cell lymphoma after receiving androgen deprivation therapy.
- The diagnosis was confirmed through symptoms like dyspnea and back pain, and immunohistochemistry showed a positive estrogen receptor β, suggesting estrogen suppression contributed to the lymphoma's progression.
- Following the cessation of hormone therapy and initiation of R-CHOP treatment, the patient's lymphoma significantly improved, highlighting the important role of estrogen in such cases and the need for careful treatment selection in similar patients.
Background: Although nivolumab plus ipilimumab is the standard treatment for metastatic renal cell carcinoma (RCC), its efficacy and safety in older patients remain unclear. Therefore, this study aimed to assess the clinical outcomes of nivolumab plus ipilimumab for metastatic RCC in patients aged ≥ 75 years.
Methods: We enrolled 120 patients with metastatic RCC treated with nivolumab plus ipilimumab from August 2015 to January 2023.